Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CFB | P00751 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051645 | 0.88 | AXL (0.34) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL20939366 | 0.79 | P2RX7 (0.42) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL22328043 | 0.74 | AXL (0.34) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL19420465 | 0.74 | ACHE (0.39) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL1146475 | 0.73 | P2RX7 (0.40) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL31549623 | 0.73 | CFB (0.40) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL18683281 | 0.72 | P2RX7 (0.38) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL1465882 | 0.71 | AHR (0.42) | P2RX7AXLPRKCIAURKATPX2 | |
| SCHEMBL12278257 | 0.70 | AHR (0.38) | P2RX7AXLPRKCIAHRCCR8 | |
| SCHEMBL26077500 | 0.70 | AURKA (0.38) | P2RX7AXLPRKCIAURKATPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | P2RX7 3928/4885AXL 1914/4885PRKCI 379/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | P2RX7 3221/4885AXL 1347/4885PRKCI 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.